Comparative Pharmacology
Head-to-head clinical analysis: METHYLENE BLUE versus PROVAYBLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLENE BLUE versus PROVAYBLUE.
METHYLENE BLUE vs PROVAYBLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylene blue is a dye that acts as a redox agent, reducing methemoglobin to hemoglobin by activating the enzyme methemoglobin reductase. It also inhibits nitric oxide synthase and guanylate cyclase, causing vasoconstriction in septic shock.
Methylthioninium chloride (methylene blue) acts by reducing methemoglobin to hemoglobin via the enzyme NADPH methemoglobin reductase, thereby restoring oxygen-carrying capacity of the blood.
1-2 mg/kg IV over 5-30 minutes for methemoglobinemia; repeat after 1 hour if needed. Maximum dose: 7 mg/kg.
1-2 mg/kg intravenously over 5 minutes, may repeat once if needed. Maximum single dose: 300 mg.
None Documented
None Documented
Clinical Note
moderateMethylene blue + Torasemide
"Methylene blue may increase the hypotensive activities of Torasemide."
Clinical Note
moderateMethylene blue + Travoprost
"Methylene blue may increase the hypotensive activities of Travoprost."
Clinical Note
moderateMethylene blue + Unoprostone
"Methylene blue may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateMethylene blue + Hydrochlorothiazide
Terminal elimination half-life approximately 12–24 hours; clinically, levels may persist for 2–3 days due to enterohepatic recycling
Terminal elimination half-life is approximately 10-15 hours. In patients with renal impairment, half-life may be prolonged; no dose adjustment recommended for mild-to-moderate impairment, but use caution in severe impairment.
Renal (80% as leukomethylene blue and unchanged drug); biliary/fecal minor
Primarily renal excretion as unchanged drug. Approximately 45-60% of a dose is excreted unchanged in urine. Minor fecal elimination accounts for less than 10%.
Category C
Category C
Antidote
Antidote
"Methylene blue may increase the hypotensive activities of Hydrochlorothiazide."